H. Bear

D. Conrad, H. Bear, S. Grant, 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

S. Paik, G. Tang, J. Costantino, 2015, The Lancet. Oncology.

Image‐guided breast biopsy—how, when, and by whom?

H. Bear, 1998, Journal of surgical oncology.

Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy

P. Fisher, Xia Li, H. Bear, 2021, Cancer Research.

Neighborhood disadvantage and biological aging biomarkers among breast cancer patients

W. Chow, H. Bear, B. Fuemmeler, 2022, Scientific Reports.

Despite limited data, coexistent lobular carcinoma in situ should not be a contraindication to breast conservation for women with invasive breast carcinoma

H. Bear, M. Grimes, W. Hans Carter, 2000, Cancer.

Why not breast conservation?

H. Bear, 1993, Journal of surgical oncology.

Long-term results of breast conservation therapy for breast cancer.

H. Bear, D. Arthur, W. Lawrence, 1996, Annals of surgery.

Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2

H. Bear, M. Manjili, M. Kmieciak, 2009, Cancer Immunology, Immunotherapy.

Mast cell histamine promotes the immunoregulatory activity of myeloid‐derived suppressor cells

D. Conrad, H. Bear, J. Ryan, 2014, Journal of leukocyte biology.

Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2015 .

Breast conservation therapy rates are no different in medically indigent versus insured patients with early stage breast cancer

H. Bear, L. Penberthy, S. Karp, 2003, Journal of surgical oncology.

Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.

H. Rockette, D. Wickerham, N. Wolmark, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation.

T. Smith, H. Bear, D. Wazer, 1999, International journal of radiation oncology, biology, physics.

Prognosis of level V malignant melanoma

H. Bear, J. Neifeld, S. Kay, 1985, Cancer.

Colon and rectal carcinoma in the west of Scotland. Symptoms, histologic characteristics, and outcome.

H. Bear, R. Wilson, J. Macintyre, 1984, American journal of surgery.

Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets

H. Bear, M. Manjili, J. Koblinski, 2020, Breast Cancer Research.

Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma

H. Bear, Christine K. Zoon, W. Wan, 2017, International journal of molecular sciences.

Addition of Interleukin-21 for Expansion of T-Cells for Adoptive Immunotherapy of Murine Melanoma

H. Bear, Christine K. Zoon, W. Wan, 2015, International journal of molecular sciences.

Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma

H. Bear, L. Graham, C. Miller, 2010, BMC Immunology.

Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells

C. Gennings, H. Bear, D. Gewirtz, 2010, Breast Cancer Research and Treatment.

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

H. Bear, M. Manjili, M. Feldmesser, 2009, Cancer Immunology, Immunotherapy.

Bryostatin 1-activated T cells can traffic and mediate tumor regression.

H. Bear, T. Inge, T. Tuttle, 1992, The Journal of surgical research.

The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer

D. Conrad, H. Bear, C. Camarena, 2019, BMC Immunology.

Myeloid‐derived suppressor cells enhance IgE‐mediated mast cell responses

D. Conrad, H. Bear, J. Ryan, 2014, Journal of leukocyte biology.

Cutting Edge: Mast Cells Critically Augment Myeloid-Derived Suppressor Cell Activity

D. Conrad, H. Bear, J. Ryan, 2012, The Journal of Immunology.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

D. Cescon, B. Vincent, S. Adams, 2019, npj Breast Cancer.

IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo

H. Bear, M. Manjili, L. Graham, 2010, Breast Cancer Research and Treatment.

Activation and expansion of cytotoxic T lymphocytes from tumor-draining lymph nodes

H. Bear, T. Inge, S. Hoover, 2005, Cancer Immunology, Immunotherapy.

Bryostatin/ionomycin-activated T cells mediate regression of established tumors.

H. Bear, G. Hamad, L. Graham, 2001, The Journal of surgical research.

Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients.

D. S. Lind, J. L. Frank, H. Bear, 1993, Surgical oncology.

Production of tumor-specific suppressor T cell hybridomas.

H. Bear, 1987, The Journal of surgical research.

Papillary lesions of the breast: To excise or observe?

H. Bear, G. Cardenosa, K. Archer, 2018, The breast journal.

Biologic therapy of melanoma with cytokines and lymphocytes.

H. Bear, G. Hamad, P. Kostuchenko, 1996, Seminars in surgical oncology.

Differential sensitivity of cytotoxic T lymphocytes and lymphokine-activated killer cells to inhibition by L-ornithine.

D. S. Lind, H. Bear, B. Susskind, 1991, Cellular immunology.

Phenotypic and functional heterogeneity of thymic and splenic lymphokine activated killer cells relative to ornithine sensitivity.

H. Bear, B. Susskind, P. Mehrotra, 1991, Cellular immunology.

Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy

H. Bear, D. Gewirtz, M. Manjili, 2018, Oncotarget.

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

Sung-Bae Kim, K. Gelmon, H. Rugo, 2022, Frontiers in Oncology.

Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.

H. Bear, T. Inge, B. Susskind, 1992, Cancer research.

Methyl-Binding Domain Protein 2–Dependent Proliferation and Survival of Breast Cancer Cells

H. Bear, O. Mian, M. Gnanapragasam, 2011, Molecular Cancer Research.

Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma

H. Bear, G. Hamad, Christin E Bland, 1997, Annals of Surgical Oncology.

A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim

H. Bear, P. Dillon, T. Millard, 2022, Case reports in oncological medicine.

Modified breast cancer model for preclinical immunotherapy studies.

S. Spiegel, H. Bear, K. Takabe, 2016, The Journal of surgical research.

Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer

H. Bear, Amy H Tang, R. Hoefer, 2022, Cancer drug resistance.

Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer

W. Curran, M. Scheier, G. Gustafson, 2019, General Session Abstracts.

Can we now reach a consensus on the management of benign papillary breast lesions?

H. Bear, Sidrah Khan, 2019, Annals of Breast Surgery.

Phase Ib trial of bryostatin 1 in patients with refractory malignancies.

H. Bear, S. Grant, E. Poplin, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adoptive Transfer of Bryostatin‐Activated Tumor‐Sensitized Lymphocytes Prevents or Destroys Tumor Metastases Without Expansion In Vitro

H. Bear, M. Fleming, K. Lipshy, 1995, Journal of Immunotherapy with Emphasis on Tumor Immunology.

Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation.

H. Bear, M. Manjili, A. Toor, 2011, Journal of visualized experiments : JoVE.

Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial

John D. Roberts, H. Bear, M. B. Tombes, 2001, Cancer Immunology, Immunotherapy.

Protective role of IL-2 during activation of T cells with bryostatin 1.

H. Bear, F. Kos, D. Cornell, 2000, International journal of immunopharmacology.

Formal hepatic resection of colorectal liver metastases. Ploidy and prognosis.

D. S. Lind, H. Bear, G. Parker, 1992, Annals of surgery.

Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes.

R. Merchant, H. Bear, N. Baldwin, 1997, Neurological research.

Different signaling pathways induced by alpha-CD3 monoclonal antibody versus alloantigen on the basis of differential ornithine sensitivity.

D. S. Lind, H. Bear, B. Susskind, 1992, Cellular immunology.

Postischemic extremities exhibit immediate release of tumor necrosis factor.

H. Bear, A. Fowler, T. Tuttle, 1994, Journal of vascular surgery.

Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.

Barbara L. Smith, Michael J. Miller, L. Esserman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ability of low-dose cyclophosphamide to overcome metastasis-induced immunosuppression

H. Bear, T. Inge, T. Tuttle, 2006, Annals of Surgical Oncology.

Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.

H. Bear, Bina Patel, L. Graham, 2004, International immunology.

gamma-Interferon plays a key role in T-cell-induced tumor regression.

H. Bear, T. Inge, T. Tuttle, 1993, Cancer research.

Bryostatin 1 activates T cells that have antitumor activity.

J. L. Frank, H. Bear, T. Inge, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function

F. Marincola, H. Bear, M. Manjili, 2009, Journal of Translational Medicine.

Intraoperative Injection of Radiocolloid for Sentinel Node Biopsy in Breast Cancer

H. Bear, H. Vu, M. Fratkin, 2013, The Journal of Nuclear Medicine Technology.

Effects of N-N-Dimethyltryptamine on retention of startle response habituation in the rat

Michael Davis, H. Bear, 2004, Psychopharmacologia.

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients

F. Marincola, P. Ascierto, H. Khalak, 2013, Journal of Translational Medicine.

Randomized sham controlled trial of cranial microcurrent stimulation for symptoms of depression, anxiety, pain, fatigue and sleep disturbances in women receiving chemotherapy for early-stage breast cancer

H. Bear, R. Elswick, D. Kelly, 2015, SpringerPlus.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

D. Cescon, B. Vincent, S. Adams, 2019, npj Breast Cancer.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

G. Hortobagyi, B. Vincent, S. Adams, 2019, JAMA oncology.

DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer

H. Bear, M. Manjili, K. Payne, 2016, Cancer Immunology, Immunotherapy.

Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity

H. Bear, T. Turk, S. Hoover, 2005, Cancer Immunology, Immunotherapy.

Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.

H. Bear, 1986, Cancer research.

A signature of immune function genes associated with recurrence-free survival in breast cancer patients

F. Marincola, H. Bear, E. Wang, 2012, Breast Cancer Research and Treatment.

Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial

H. Bear, A. Robidoux, Angel A. Rodriguez, 2017, Journal of surgical oncology.

Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies

E. Petricoin, M. Goetz, H. Bear, 2020, Cancers.

If we build it they will come: targeting the immune response to breast cancer

D. Cescon, S. Adams, H. McArthur, 2019, npj Breast Cancer.

Signaling and Regulation Methyl-Binding Domain Protein 2 – Dependent Proliferation and Survival of Breast Cancer Cells

H. Bear, O. Mian, M. Gnanapragasam, 2011 .

If we build it they will come: targeting the immune response to breast cancer

D. Cescon, S. Adams, H. McArthur, 2019, npj Breast Cancer.

A Phase II Study of 3′-Deoxy-3′-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688

Fenghai Duan, Mark Muzi, Linda Hovanessian-Larsen, 2015, The Journal of Nuclear Medicine.

Surgical Oncology Evaluation and Management of Breast Diseases

H. Bear, 2018 .

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells

H. Bear, M. Manjili, K. Knutson, 2010, Breast Cancer Research and Treatment.

Perceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal Study

H. Bear, R. Elswick, C. Jackson-Cook, 2015, PloS one.

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients

F. Marincola, P. Ascierto, H. Khalak, 2013, Journal of Translational Medicine.

Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.

H. Bear, T. Inge, T. Tuttle, 1992, Cancer research.

Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden.

S. Spiegel, H. Bear, K. Takabe, 2013, Surgery.

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

H. Rockette, N. Wolmark, H. Bear, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Localized Breast Cancer : Recent Developments Regarding Diagnosis and Management

H. Bear, W. Lawrence, 2005 .

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

S. Paik, G. Tang, J. Costantino, 2013, The Lancet. Oncology.

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Norman Wolmark, Soonmyung Paik, S. Paik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Biliary Obstruction in Patients with Unresectable Carcinoma of the Pancreas

H. Bear, G. Parker, W. Lawrence, 1989, Annals of surgery.

Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide

J. L. Frank, H. Bear, T. Inge, 1992, Cancer Immunology, Immunotherapy.

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2017, Annals of Surgical Oncology.

Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.

J. J. Miralles, S. Loibl, H. Joensuu, 2022, European journal of cancer.

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

A. Schneeweiss, C. Denkert, A. Buzdar, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.

H. Bear, S. Goble, 2003, The Surgical clinics of North America.

Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

F. Marincola, H. Bear, E. Wang, 2008, Cancer research.

35 – Approaches to Adoptive Immunotherapy

H. Bear, C. Chin, 2001 .

Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.

H. Bear, M. Manjili, K. Payne, 2014, Future oncology.

Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse

Lisa L. Smith, H. Bear, A. Yacoub, 2011, The Journal of Immunology.

Bevacizumab and breast cancer: what does the future hold?

H. Bear, K. Takabe, C. Stevenson, 2012, Future oncology.

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

G. Tang, J. Costantino, C. Geyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.

Stewart J Anderson, Norman Wolmark, James J Dignam, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

James A Young, Norman Wolmark, Rita S Mehta, 2012, The New England journal of medicine.

Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

T. Julian, D. Wickerham, N. Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of biliary obstruction caused by metastatic cancer.

H. Bear, G. Parker, M. Turner, 1989, American journal of surgery.

A gene transcription signature of obesity in breast cancer

C. Creighton, Jenny C. Chang, Yiqun Zhang, 2012, Breast Cancer Research and Treatment.

Phase II study of 3'-deoxy-3'-18F fluorothymidine PET/CT (FLT-PET) in the assessment of early response in locally advanced breast cancer (LABC): Preliminary results of ACRIN 6688.

Jean B. Cormack, D. Mankoff, P. Jolles, 2014 .

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Sung-Bae Kim, C. Denkert, K. Gelmon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy.

H. Bear, 2010, Surgical oncology clinics of North America.

Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial

W. Curran, M. Scheier, H. Kuerer, 2019, The Lancet.

Indications for neoadjuvant chemotherapy for breast cancer.

H. Bear, 1998, Seminars in Oncology.

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial: Boughey JC, for the Alliance for Clinical Trials in Oncology (Mayo Clinic, Rochester, MN; et al) JAMA 310:1455-1461, 2013 §

H. Bear, L. Fernandez, 2014 .

Phenotype of syngeneic tumor-specific cytotoxic T-lymphocytes and requirements for their in vitro generation from tumor-bearing host and immune spleens.

H. Bear, B. Susskind, K. Close, 1988, Cancer research.

A cytotoxic T-lymphocyte clone derived from mice with progressively growing tumors.

J. L. Frank, H. Bear, T. Inge, 1991, Archives of surgery.

Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis

H. Bear, M. Manjili, Johanna K. Morales, 2009, Breast Cancer Research and Treatment.

Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells

H. Bear, M. Manjili, Christine K. Zoon, 2013, Breast Cancer Research and Treatment.

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity

H. Bear, E. Repasky, Xiaofei Yu, 2021, Journal for ImmunoTherapy of Cancer.

Measuring circulating tumor cells as a surrogate end point for adjuvant therapy of breast cancer: what do they mean and what should we do about them?

H. Bear, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab

Krishna R. Kalari, Erin E. Carlson, P. Fasching, 2018, Pharmacogenetics and genomics.

The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with met

D. Wickerham, A. Glass, H. Bear, 1994, American journal of clinical oncology.

Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13)

K. Gelmon, M. Gnant, A. Makris, 2013 .

Immunomodulatory effects of transforming growth factor-beta on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes.

H. Bear, T. Inge, B. Susskind, 1992, Journal of immunology.

The Role of Margin Status and Reexcision in Local Recurrence Following Breast Conservation Surgery

H. Bear, L. Wolfe, C. Stevenson, 2013, Annals of Surgical Oncology.

Angiopoietin pathway gene expression associated with poor breast cancer survival

H. Bear, M. Dozmorov, K. Takabe, 2017, Breast Cancer Research and Treatment.

Estimating the cost-effectiveness of stereotaxic biopsy for nonpalpable breast abnormalities: a decision analysis model.

L. Fajardo, B. Hillner, H. Bear, 1996, Academic radiology.

Diagnosis and Management of Breast Tumors

C. Geyer, H. Bear, D. Arthur, 2018, Springer International Publishing.

Tumor Bed Boost Omission After Negative Re-Excision in Breast-Conservation Treatment

H. Bear, D. Wazer, D. Arthur, 2006, Annals of Surgical Oncology.

Do surgical oncologists achieve lower rates of local‐regional recurrence in node positive breast cancer treated with mastectomy alone?

H. Bear, S. Latosinsky, 2001, Journal of surgical oncology.

Complications of mastectomy and their relationship to biopsy technique

W. Frable, H. Bear, W. Lawrence, 1996, Annals of Surgical Oncology.

Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters

H. Bear, K. McGuire, 2019, Annals of Surgical Oncology.

Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation

H. Bear, 2010 .

Axillary Node Management in Patients Receiving Neoadjuvant Chemotherapy

H. Bear, L. Fernandez, 2015, Current Breast Cancer Reports.

Reaping the harvest from neoadjuvant therapy for breast cancer: Reducing morbidity with sentinel lymph node biopsy

H. Bear, 2007, Journal of surgical oncology.

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure

H. Bear, E. Wang, M. Manjili, 2011, Journal of Translational Medicine.

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

S. Paik, G. Tang, C. Geyer, 2023, Breast Cancer Research and Treatment.

Earlier Chemotherapy for Breast Cancer: Perhaps Too Late But Still Useful

H. Bear, 2003, Annals of surgical oncology.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.

S. Paik, G. Tang, J. Costantino, 2016 .

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells

H. Bear, M. Manjili, A. Toor, 2016, Journal of leukocyte biology.

Taking action on the volume-quality relationship: how long can we hide our heads in the colostomy bag?

Thomas J. Smith, Thomas J Smith, B. Hillner, 2003, Journal of the National Cancer Institute.

Near-Infrared Imaging of Adoptive Immune Cell Therapy in Breast Cancer Model Using Cell Membrane Labeling

G. Sundaresan, H. Bear, J. Zweit, 2014, PloS one.

Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients

J. J. Miralles, S. Loibl, M. Mackelenbergh, 2020 .

Insurance and inpatient care

H. Bear, C. Bradley, B. Dahman, 2012, Cancer.

Cosmetic Outcome from Post Lumpectomy Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 Phase III Clinical Trial

G. Gustafson, T. Julian, F. Vicini, 2019, International Journal of Radiation Oncology*Biology*Physics.

Collaborative Initiatives in the Care of Early Stage Breast Cancer: Reduction in Variation of Breast‐Conserving Therapy

R. Boudreau, H. Bear, L. Penberthy, 2000, The breast journal.

Taxanes as Primary Chemotherapy for Early Breast Cancer: Meta-analysis of Randomized Trials

H. Bear, 2009 .

Gr1−/lowCD11b−/lowMHCII+ myeloid cells boost T cell anti‐tumor efficacy

H. Bear, M. Manjili, M. Idowu, 2018, Journal of leukocyte biology.

Cancer in the FVBN202 Transgenic Mouse Adoptive Cellular Therapy against Breast Suppressor Cells and Result in an Effective Cells Resistant to Myeloid-Derived Activated NKT Cells and NK Cells Render T

Lisa L. Smith, H. Bear, A. Yacoub, 2011 .

Impact of Medicaid disenrollment in Tennessee on breast cancer stage at diagnosis and treatment

David W Harless, H. Bear, L. Sabik, 2017, Cancer.

Activation of CD8+ murine T cells from tumor-draining lymph nodes by phorbol dibutyrate plus calcium ionophore.

H. Bear, T. Inge, T. Tuttle, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Appropriate Margin Width in Breast-Conserving Surgery

Amelia C. Grover, H. Bear, T. McKenzie-Johnson, 2010 .

Expansion of melanoma-specific lymphocytes in alternate gamma chain cytokines: gene expression variances between T cells and T cell subsets exposed to IL-2 versus IL-7/15

H. Bear, C. Dumur, Christine K. Zoon, 2014, Cancer Gene Therapy.

Stage III breast cancer: Is neoadjuvant chemotherapy always necessary?

J. L. Frank, D. McClish, H. Bear, 1992, Journal of surgical oncology.

Noninvasive Breast Cancer

H. Bear, Tania K. Arora, 2015 .

Completion axillary lymph node dissection for breast cancer: immediate versus delayed versus none.

H. Bear, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CompletionAxillaryLymphNodeDissectionforBreast Cancer:ImmediateVersusDelayedVersusNone

H. Bear, 2008 .

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.

S. Paik, G. Tang, J. Costantino, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

J. Bryant, D. Wickerham, H. Bear, 2023, Journal of Clinical Oncology.

The epigenetic regulation of cancer cell recovery from therapy exposure and its implications as a novel therapeutic strategy for preventing disease recurrence.

H. Bear, P. Dent, S. Grant, 2023, Advances in cancer research.

Mast cells and mast cell-derived IL-13 play an important role in MDSC activation, migration, and accumulation. (TUM4P.925)

D. Conrad, H. Bear, J. Ryan, 2014, Journal of Immunology.

Sentinel node micrometastases and non-sentinel nodes in breast cancer: how much do we need to know?

H. Bear, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast Cancer Research and Treatment 2001 Reviewers

D. Berry, L. Holmberg, D. Alberts, 2004, Breast Cancer Research and Treatment.

Variation in the use of breast-conserving therapy for Medicare beneficiaries in Virginia: clinical, geographic, and hospital characteristics.

R. Boudreau, H. Bear, L. Penberthy, 1998, Clinical performance and quality health care.